Layer 1


sab_image_header (14K)

SCIENTIFIC ADVISORY BOARD:

Dr. Don Lamm, MD
is a world recognized pioneer in the field of urology. He is a former Professor of Urology at Mayo Medical School and former Professor and Chairman of the Department of Urology, West Virginia University. Dr. Lamm developed the bacillus Calmette-Guérin (BCG) immunotherapy. BCG is considered the gold standard for treatment of superficial bladder cancer.

After 28 years of academic practice, Dr. Lamm established and is President of BCG Oncology PC. BCG specializes in treatment of Bladder Cancer and Genitourinary Oncology. BCG Oncology, P.C. 16620 N. 40th St. Suite E, Phoenix AZ 85032 (Phone 602 493 6626)

Dr. Lamm served his residency at University of California, San Diego, Calif. Dr. Lamm is a scientific reviewer for Cancer, European Urology, Nutrition, Journal of Urology, Urology. He has PUBLISHED OVER 270 original papers in refereed journals, 50 book chapters, 130 abstracts and published scientific presentations.
www.bcgoncology.com

Dr. Jack Summers, MD, Ph.D
Dr. Summers is Emeritus Professor of Urology and former Department Chairman at the Northeastern Ohio Universities College of Medicine and Summa Health Care System. Dr. Summers and Dr. Diokno conducted the pilot study for Apatone. Dr. Summers is now retired from practice and continues to be interested in the educational activities of Summa Health System Core Basic Science Research Laboratory.
Dr. Ananias Diokno, MD
Urologist and chief of urology at William Beaumont Hospital, Royal Oak, MI. Dr. Diokno is a worldwide expert in female urology and neurogenic bladder dysfunction. He served as President (1996-1997) for the American Urological Association N. Central Section. Dr. Diokno is past Co-chair for the agency in charge of health care policy and research urinary incontinence clinical guidelines. Recipient (1989), NIH (National Institutes of Health) merit award.
http://www.beaumonthospitals.com/pls/cportal30/pris.physrefPkg1.get_phys_info?p_id=3502
Dr. James Jamison, Ph.D
Cancer Cell Biologist. Research Associate Professor of Urology, Northeastern Ohio Universities College of Medicine; Developing natural products or combinations of natural products as antitumor agents. Dr. Jamison has published extensively on the subject of anti-neoplastic activity induced by natural products. Discovered autoschizis in conjunction with Dr. Jacques Gilloteaux and other cancer researchers.
Dr. Chun-Che Tsai, Ph.D
is a world renown expert on QSAR (Quantitative Structure Activity Relationship). His expertise includes interaction of drugs with nucleic acids; anticancer/antiviral drugs, and interferon inducers together with structure/function relationships; X-ray diffraction and QSAR. http://dept.kent.edu/chemistry/Faculty/Research/tsai.htm
Dr. Jacques Gilloteaux, Ph.D
Professor, American University of the Caribbean, School of Medicine. Dr. Gilloteaux has published more than 130 publications, made over
150 presentations and written numerous book chapters on topics including cancer biology (male and female reproduction systems), muscle tissues and exercise and the biology of aging. In collaboration with other cancer researchers, Dr. Gilloteaux is credited with the discovery of a novel, non-necrotic, non-apoptotic cell death named "Autoschizis".
Dr. Pedro (Buc) Calderon, Ph.D
Head of the Unité de Pharmacocinétique, Métabolisme, Nutrition et Toxicologie, Department of Pharmaceutical Sciences, Catholic University of Louvain, Brussels, Belgium. Dr. Calderon is Director of post-graduate, graduate and undergraduate research activities at the University. He is active in the field of cancer research and has conducted, supervised, written and co-authored more than twelve related papers over the past five years.
Dr. Charles Edwards, MD
San Diego, CA - is former Director of the FDA. He is past President and CEO of Scripps Clinic and Research Foundation, La Jolla, CA as well as the former President and CEO of Scripps Institutes of Medicine and Science.
http://www.fda.gov/oc/commissioners/edwards.html
Yang Yun, Ph.D
is Assistant Professor, Department of Biomedical Engineering at the University of Akron. He is a CAREER Award recipient from the National Scientific Foundation and is a principal investigator for IC-MedTech sponsored research involving nanoscale polymer drug delivery systems termed LCB's (Liquid Crystal Biomedics). Dr. Yun's research interests include biomaterial development, characterization, gene therapy, drug delivery, tissue engineering, nanotechnology and cardiovascular dynamics and mechanics.
http://www.biomed.uakron.edu/fs-yun.php

© 2007 IC-MedTech